Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Could US Solve Drug Shortages With 'Heightened' M&A Scrutiny?

Executive Summary

FDA's inter-agency drug shortage task force wants comments on whether new shortage prevention and mitigation policies should include closer examination of mergers and acquisitions that could create drug shortages.

Related Content

To Lower Drug Prices, Look At Generic Industry Health Rather Than FDA, Woodcock Says
The Economics Of Drug Shortages: US FDA Seeks Broad Input
Who Wants To Be 'Essential'? US FDA Considers Critical Drugs List
FDA Shortages Task Force Looks More Broadly To Tackle Root Causes
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
Code Cart Crisis: Anatomy Of An Emergency Drug Shortage
Pfizer Finally Sealing Hospira Deal


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts